The breast cancer "plunge" after initial publication of the WHI results: An alternative explanation

Maturitas

Volumn 66, Issue 3, 2010, Pages 277-284

  Simon, James A ^a,b   Nahum, Gerard G ^c   Stanislaw, Harold ^d   Gaines, Tatiana ^b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b Women's Health and Research Consultants   (United States)

^c BAYER CORPORATION   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; ERT; Estrogen only therapy; Estrogen progestin therapy; ET; Hormone therapy; HRT; HT; SEER 9 database; WHI study

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN; PLACEBO;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CONTROLLED STUDY; ENDOMETRIUM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; WOMEN'S HEALTH;

AGED; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INCIDENCE; MENOPAUSE; MIDDLE AGED; PROGESTERONE; UNITED STATES; WOMEN'S HEALTH;

EID: 77952984283     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.03.011     Document Type: Article

References (37)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350 (1997) 1047-1059
2. Beral V., and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
3. Schwartz L.M., and Woloshin S. The media matter: a call for straightforward medical reporting. Ann Intern Med 140 (2004) 226-228
4. Rossouw J.E., Anderson G.L., Prentice R.L., et al., Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
5. Steering Committee for the Women's Health Initiative. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
6. Stefanick M.L., Anderson G.L., Margulis K.L., et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295 (2006) 1647-1657
7. Simon, JA. Management issues. NAMS Menopause e-Consult. Available at http://www.menopause.org/ME0707.pdf [accessed October 20, 2008]; July 2007;3:3-6.
8. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 (2003) 3243-3253
9. Ravdin P.M., Cronin K.A., Howlander N., Chlebowski R.T., and Berry D.A. A sharp decrease in breast cancer incidence in the United States in 2003, 29th Annual San Antonio Breast Cancer Symposium. Breast Cancer Res Treat 100 Suppl. 1 (2006) S6
10. Ravdin P.M., Cronin K.A., Howlander N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (2007) 1670-1674
11. Information derived by Bayer HealthCare from data provided by Wolters Kluwer Health, Source (R) Retail data; 2001-2008.
12. Dietel M., Lewis M.A., and Shairo S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: A mini-review. Hum Reprod 20 (2005) 2052-2060
13. Berry D.A., Cronin K.A., Plevritis S.K., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353 (2005) 1784-1792
14. Glass A.G., Lacey J.V., Carreon J.D., and Hoover R.N. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99 15 (2007) 1152-1161
15. Ravdin P.M., Cronin K.A., Chlebowski R.T., et al. A decline in breast-cancer incidence. N Engl J Med 357 (2007) 509-513
16. Kliewer E.V., Demers A.A., and Nugent Z.J. A decline in breast-cancer incidence. N Engl J Med 357 (2007) 509-510
17. Zahl P.-H., and Maehlen J. A decline in breast-cancer incidence. N Engl J Med 357 (2007) 510-511
18. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
19. Heiss G., Wallace R., Anderson G.L., et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 299 (2008) 1036-1045
20. SEER Cancer Statistics Review. Available at http://seer.cancer.gov/csr/1975_2005/ [accessed October 20, 2008]; 1975-2005.
21. SEER Cancer Statistics. URL: http://seer.cancer.gov/faststats/selections.php?series=race.
22. SEER Cancer Statistics. URL: http://seer.cancer.gov/registries/data.html.
23. SEER Cancer Statistics. URL: http://seer.cancer.gov/stdpopulations/stdpop.19ages.html.
24. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 19 (1998) 61-109
25. Simon J.A., Wysocki S., Brandman J., and Axelsen K. A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users. Menopause 10 (2003) 37-44
26. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291 1 (2004) 47-53
27. Haas J.S., Kaplan C.P., Gerstenberger E.P., and Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140 3 (2004) 184-188
28. Schindler A.E., Campagnoli C., Druckmann R., et al. Classification and pharmacology of progestins. Maturitas 46S1 (2003) S7-S16
29. Otto C., Fuchs I., Altmann H., et al. Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate. Endocrinology 149 (2008) 3952-3959
30. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107 (2008) 103-111
31. FDA Guidance for Industry. Noncontraceptive estrogen drug products for the treatment of vasomotor symptoms and vulvar and vaginal atrophy symptoms - recommended prescribing information for health care providers and patient labeling. Available at http://www.fda.gov/cder/guidance/6932dft.pdf [accessed February 9, 2009].
32. Kerlikowske K., Miglioretti D.L., Ballard-Barbash R., et al. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21 (2003) 4314-4321
33. Ioannidis J.P.A. Why most published research findings are false. PLoS Med 2 8 (2005) e124
34. Lobo R. Evidence-based medicine and the management of Menopause [evidence-based approach to menopause]. Clin Obstet Gynecol 51 3 (2008) 534-538
35. Zhang J., and Yu K.F. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 280 (1998) 1690-1691
36. McNutt L.A., Wu C., Wue X., and Hafner J.P. Estimating the relative risk in cohort studies and clinical trials of common outcomes. J Epidemiol 157 (2003) 940-943
37. Simon S. Understanding the odds ratio and the relative risk. J Androl 22 (2001) 533-536